United States Patent 5,472,969: Claim Scope, Miglustat Coverage, Expiration, and Patent Landscape

U.S. Patent No. 5,472,969 covers methods of treating Gaucher's disease with N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, an iminosugar class that includes miglustat, the N-butyl derivative. The broadest claim covers N-alkyl groups containing two through eight carbon atoms. The patent issued on December 5, 1995, and its enforceable term expired in 2013 under the applicable pre-1995 filing-date patent-term rules. The patent is therefore historically important but no longer creates a blocking patent barrier to generic miglustat development.

What does U.S. Patent 5,472,969 cover?

The patent claims a therapeutic method, not the chemical compound as such.

Claim	Scope	Covered examples
1	Treating Gaucher's disease with a glycolipid-inhibitory effective amount of an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol, where the alkyl group has 2-8 carbons	Ethyl through octyl derivatives, subject to the patent's construction of "alkyl"
2	Claim 1 limited to an alkyl group containing 4-6 carbons	Butyl, pentyl and hexyl derivatives
3	Claim 2 limited to a butyl group	N-butyl derivative, miglustat
4	Claim 2 limited to a hexyl group	N-hexyl derivative

The patent's operative concept is substrate-reduction therapy. The claimed compounds inhibit glycolipid biosynthesis, reducing the production of glucosylceramide that accumulates in Gaucher's disease because of deficient lysosomal glucocerebrosidase activity. U.S. Patent No. 5,472,969.

What compound is covered by claim 3?

Claim 3 covers miglustat, also known as N-butyldeoxynojirimycin or NB-DNJ. Miglustat is marketed in the United States as Zavesca for certain patients with mild-to-moderate type 1 Gaucher's disease who are unsuitable for enzyme replacement therapy. FDA labeling also identifies an indication for treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick disease type C. FDA, 2023.

Claim 3 is narrower than claim 1 but commercially more significant because it identifies the principal marketed Gaucher compound associated with the patent.

Does the patent claim miglustat as a chemical compound?

No. The issued claims provided are method-of-treatment claims. They require:

A patient affected with Gaucher's disease;
Administration to that patient;
A claimed N-alkyl derivative of the iminosugar scaffold; and
An amount effective to inhibit glycolipids.

A claim directed solely to miglustat's composition, crystalline form, salt, formulation, manufacturing process or pharmaceutical composition would have a different infringement analysis. Those categories are not present in the four claims supplied.

How broad is claim 1 of U.S. Patent 5,472,969?

Claim 1 is a genus claim covering N-alkyl derivatives with alkyl groups containing two to eight carbon atoms. It potentially covers:

N-ethyl;
N-propyl;
N-butyl;
N-pentyl;
N-hexyl;
N-heptyl; and
N-octyl derivatives.

The claim is not limited to oral administration, a particular dose, a particular formulation, monotherapy, disease severity or treatment duration. It also does not identify a specific glycolipid, inhibitor concentration or pharmacokinetic profile.

The phrase "glycolipid inhibitory effective amount" is a functional limitation. A compound would need to be administered in an amount that satisfies the therapeutic and inhibitory requirements of the claim. The claim does not state a numerical dose. That creates potential claim-construction and proof issues, but it does not convert the claim into a composition claim.

The phrase "alkyl" ordinarily refers to a saturated hydrocarbon substituent. Depending on the patent specification and prosecution history, the term may include straight-chain and branched-chain groups. The supplied claims alone do not establish whether the patentee narrowed that term during prosecution. For infringement analysis, the issued patent, file history and controlling claim-construction law would be required.

What is the relationship between claims 1, 2, 3 and 4?

Claims 2, 3 and 4 are dependent claims. Each incorporates the limitations of the preceding claim.

Claim 2 covers only the C4-C6 subset of claim 1. Claim 3 then narrows claim 2 to butyl. Claim 4 narrows claim 2 to hexyl.

The claim hierarchy can be represented as follows:

Claim 1: C2-C8 N-alkyl derivatives
    |
    Claim 2: C4-C6 derivatives
        |-- Claim 3: N-butyl derivative, including miglustat
        |-- Claim 4: N-hexyl derivative

A product or treatment falling within claim 3 also falls within claims 1 and 2. A hexyl derivative falls within claims 1, 2 and 4. An ethyl derivative falls within claim 1 but not claims 2, 3 or 4.

What acts would have constituted infringement?

Because the claims are method claims, direct infringement would have required practicing the claimed treatment method. Under 35 U.S.C. § 271(a), that would generally involve administering a covered derivative to a patient with Gaucher's disease in a glycolipid-inhibitory effective amount.

The patent did not directly prohibit every commercial act involving miglustat. The following distinctions are material:

Activity	Relevance to the issued claims
Making miglustat	Not direct infringement of the supplied method claims by itself
Selling miglustat for Gaucher's disease	Could raise inducement issues if the patent were enforceable and the evidence supported intent
Labeling a product for Gaucher's disease	Potential inducement evidence for a live method patent
Administering miglustat to a Gaucher's patient	Conduct most directly aligned with claim 3
Selling miglustat for an unclaimed disease	Depends on label, instructions, actual use and inducement evidence
Manufacturing a formulation	Not covered as such unless the activity supported infringement of the method claims
Importing miglustat	Could implicate indirect infringement theories, but not necessarily direct infringement of these claims

For a generic applicant, the central historical risk would have been an FDA label or promotional activity that encouraged use of miglustat for Gaucher's disease while the patent remained enforceable.

When did U.S. Patent 5,472,969 expire?

U.S. Patent 5,472,969 issued on December 5, 1995. Because the application was filed before June 8, 1995, the patent was governed by the transitional patent-term rules under 35 U.S.C. § 154, which generally provided the longer of 17 years from grant or 20 years from the relevant filing date.

The patent's term expired in 2013. Public patent records identify June 4, 2013, as the relevant expiration date for the patent family. The expiration eliminated the patent as a basis for blocking later manufacture, sale or use of the claimed methods. USPTO, 2024; Google Patents, 2024.

Expiration does not erase historical infringement claims that accrued during the enforceable term, subject to the applicable limitation periods. It does prevent the patent owner from obtaining an injunction or damages for new post-expiration conduct based solely on these claims.

What was the FDA and Orange Book status of the patent?

Miglustat received FDA approval for Zavesca in 2002. The product was approved through the new drug application pathway and received orphan-drug designation for Gaucher's disease. The Gaucher's disease approval was associated with orphan-drug exclusivity, which is separate from patent protection. FDA, 2002; FDA, 2024.

Patent expiration and FDA exclusivity operated on separate timelines:

Protection	Approximate status
U.S. Patent 5,472,969	Expired in 2013
Gaucher's disease orphan-drug exclusivity	Expired years earlier, based on the 2002 approval
FDA approval of Zavesca	Remains a regulatory approval
Orange Book patent effect	No current blocking effect from Patent 5,472,969

Orange Book listing does not extend a patent's term. A listed patent can remain visible in FDA records after its legal term has ended, but an expired patent cannot support a current Paragraph IV litigation strategy or delay approval through the Hatch-Waxman patent-certification mechanism. FDA, 2024.

The patent's claims are also distinct from any later patents that might have covered a formulation, dosage regimen, polymorph, manufacturing process or a different indication. Those later rights would require separate patent-by-patent review.

Did the patent create a Paragraph IV risk for generic miglustat?

During the patent's enforceable period, a generic applicant seeking approval for a product labeled for Gaucher's disease could have faced a Paragraph IV certification risk under the Hatch-Waxman Act. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or not infringed.

For a method claim such as claim 3, the label would have been central. A generic applicant could have evaluated:

A full label that included Gaucher's disease;
A section VIII statement if the patent was not relevant to the proposed use;
A skinny label excluding the patented indication, where legally and commercially feasible;
An invalidity challenge based on prior use of iminosugars, substrate-reduction therapy or treatment of Gaucher's disease; and
A non-infringement position based on the proposed label or patient population.

Because Patent 5,472,969 expired in 2013, it no longer presents a live Paragraph IV barrier. Any current generic entry analysis must focus on unexpired patents, regulatory exclusivities and product-specific FDA requirements rather than this patent.

What patent landscape surrounds miglustat and Gaucher's disease?

The relevant landscape has four principal layers.

Method-of-treatment patents

U.S. Patent 5,472,969 is an early method patent directed to treating Gaucher's disease with N-alkyl iminosugars. Its commercial relevance came from claim 3's coverage of miglustat.

The patent's scope is narrower than a broad compound patent because it requires the Gaucher's disease treatment context. It is broader than a single-product claim because claim 1 covers multiple N-alkyl derivatives.

Composition and compound patents

Compound patents for miglustat or related iminosugars would have protected the molecule independently of the Gaucher treatment method. Such claims can create stronger manufacturing and product-sale barriers because they do not require proof that a patient was treated for a specified disease.

The supplied claims do not establish that Patent 5,472,969 contains composition claims. A complete freedom-to-operate review would therefore need to separate this patent from any compound, salt, polymorph or process patents in the same family or later families.

Formulation and dosage patents

The claims do not recite:

Capsules or tablets;
Excipients;
Modified release;
Particle size;
A specific dosage schedule;
Combination therapy;
Pediatric administration; or
A particular pharmaceutical composition.

This limits the patent's formulation coverage. A later formulation patent could have remained relevant after the expiration of the method patent, but Patent 5,472,969 itself does not provide that protection.

Competing Gaucher therapies

Miglustat competes with enzyme replacement therapies and other substrate-reduction products. Key commercial comparators include:

Therapy	Active agent or modality	Primary patent risk profile
Zavesca	Miglustat	Small-molecule method and product patents; original method patent expired
Cerdelga	Eliglustat	Later small-molecule composition, formulation and method patents
Cerezyme	Imiglucerase	Biologic manufacturing, process and regulatory exclusivity issues
VPRIV	Velaglucerase alfa	Biologic composition, production and manufacturing patents
Elelyso	Taliglucerase alfa	Recombinant biologic production and process rights
SRT and ERT competitors	Various	Differentiated by mechanism, route, manufacturing and regulatory pathway

Miglustat does not face biosimilar competition in the same way as enzyme replacement products. It is a chemically defined small molecule. The relevant competitive threat is generic entry, not a 351(k) biosimilar application.

Which companies have commercial exposure to the patent?

The patent was associated with the development and commercialization of miglustat and its Gaucher's disease indication. Oxford GlycoSciences developed the underlying program and commercial rights were later associated with larger pharmaceutical companies, including Actelion in the United States commercial history of Zavesca.

The expired patent has no current royalty or exclusionary value unless a separate contract contains post-expiration provisions unrelated to patent enforceability. Patent expiration alone does not terminate a licensing agreement, but it removes the patent-based exclusion that would normally support a product royalty or market restriction.

Revenue exposure was most material before generic competition and after FDA approval of Zavesca. The economic value of Patent 5,472,969 declined sharply after:

FDA approval and orphan exclusivity expiration;
Patent expiration in 2013; and
Availability of non-patent competitive therapies and generic development pathways.

No active patent-based launch blockade can be attributed to the four claims today.

How strong was the patent estate?

The estate was commercially valuable but structurally limited.

Strength factor	Assessment
Product relevance	High for miglustat because claim 3 identifies the N-butyl derivative
Claim breadth	Moderate; claim 1 covers C2-C8 N-alkyl derivatives
Claim type	Method-only, weaker than a composition claim for controlling manufacture and sale
Formulation coverage	None apparent from the supplied claims
Geographic reach	United States only for this patent
Current enforceability	None after 2013 expiration
Biosimilar relevance	None; miglustat is a small molecule
Generic entry risk	Historically significant, currently unrestricted by this patent
Manufacturing barrier	Not created by the supplied claims alone
Litigation leverage	Historically dependent on label and induced-use evidence

The most important commercial claim was claim 3. It directly targeted miglustat's use in Gaucher's disease, but its method format meant that enforcement against manufacturers required an indirect-infringement theory unless the manufacturer or seller itself administered the drug.

What litigation and settlement issues affect the patent?

The patent's expiration materially changes the litigation analysis. A new infringement action based solely on claims 1-4 would fail for post-expiration conduct because the statutory exclusionary term has ended.

Historical litigation analysis would focus on:

Whether the patent was listed for the relevant NDA;
Whether a generic applicant filed a Paragraph IV certification;
Whether the patent owner sued within the Hatch-Waxman statutory window;
Whether the parties entered a settlement or license before expiration;
Whether the settlement delayed generic entry; and
Whether any damages claim remained timely.

No current biosimilar litigation is implicated. Any live dispute concerning miglustat would more likely involve trademarks, supply contracts, regulatory exclusivity, pricing, product quality, or a separate unexpired patent rather than U.S. Patent 5,472,969.

Key Takeaways

U.S. Patent 5,472,969 is a method-of-treatment patent for Gaucher's disease.
Claim 1 covers N-alkyl iminosugars with C2-C8 alkyl groups.
Claim 2 narrows the scope to C4-C6 groups.
Claim 3 covers N-butyl-deoxynojirimycin, or miglustat.
Claim 4 covers the N-hexyl derivative.
The patent does not, based on the supplied claims, claim miglustat as a composition, formulation or manufacturing process.
Its term expired in 2013.
It is no longer a barrier to generic miglustat manufacture, sale or use.
The patent is not relevant to biosimilar competition.
Current freedom-to-operate analysis must examine separate compound, formulation, process, dosage and regulatory rights.

FAQs About U.S. Patent 5,472,969 and Miglustat

Does U.S. Patent 5,472,969 cover Zavesca?

Yes. Claim 3 covers the N-butyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol, which is miglustat, the active ingredient in Zavesca, when used to treat Gaucher's disease.

Can a generic company launch miglustat after the patent expired?

Yes, Patent 5,472,969 no longer blocks launch. A generic applicant must still satisfy FDA approval requirements and address any separate unexpired patents or regulatory exclusivities.

Is N-hexyl-deoxynojirimycin protected by claim 4?

Claim 4 covers treatment of Gaucher's disease with the N-hexyl derivative in a glycolipid-inhibitory effective amount. It does not cover every use, formulation or manufacturing process involving that compound.

Could the patent cover a combination treatment?

Potentially, if the combination included administration of a covered N-alkyl derivative to a Gaucher's patient in a qualifying amount. The supplied claims do not exclude combination therapy, but infringement would depend on claim construction and the specific treatment facts.

Does patent expiration eliminate orphan-drug exclusivity?

No. Patent rights and orphan-drug exclusivity are separate. Orphan exclusivity expires according to the FDA approval and designation framework, while patent rights expire under patent-term rules. Both protections associated with the original Gaucher's disease launch have ended for purposes of current market exclusion.

References

Food and Drug Administration. (2002). Zavesca (miglustat) approval letter and prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2023). Zavesca (miglustat) prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Google Patents. (2024). US5472969A: N-substituted derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of Gaucher's disease.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term expiration guidance. U.S. Department of Commerce.
35 U.S.C. §§ 154, 271.
21 U.S.C. §§ 355, 360cc.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	148456	⤷ Start Trial
Austria	268598	⤷ Start Trial
Australia	5813898	⤷ Start Trial
Australia	6783294	⤷ Start Trial
Canada	2159988	⤷ Start Trial
Canada	2278507	⤷ Start Trial
Germany	69401658	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,472,969

Summary for Patent: 5,472,969